GlucoModicum has closed +1,2MEUR Seed Round

GlucoModicum has closed +1,2M EUR Seed Round. The investment was done by experienced Finnish MedTech investors along with Business Finland. Funding round was over-subscribed.

University of Helsinki and Åbo Akademi University participated earlier 2018 to the Pre-Seed round.

GlucoModicum Oy is a Bio-Electronics start-up based in Helsinki, established in March 2018.

  • Company has developed proprietary technology related to needle-free health monitoring. Technology can serve as a platform for multiple different self-test devices.
  • Scientific proof: technology works in human tests.
  • Global patent portfolio.
  • Unique know-how & experience: GlucoModicum team has background in University of Helsinki, Åbo Akademi, Harvard, Stanford and Moscow State University.

GlucoModicum has made strong progress in miniaturizing the technology and creating the prototype.

With current funding GlucoModicum plans to finalize the early prototype and conduct early phase clinical trials. At the same time GlucoModicum has on-going engagement with high impact industrial players in Europe, US and Asia.

"We are very excited about this technology. We believe this will have an impact to medical device and diagnostics industry. Furthermore, we believe GlucoModicum is exceptionally well positioned to address this opportunity," Seed Round Lead Investor.

"We are very pleased to have on-board very experienced MedTech investors and to receive Business Finland support," Jokke Mäki, GlucoModicum Managing Director.

For a comment, please get in touch:

Jokke Mäki, Managing Director, GlucoModicum Oy, +358 40 586 0946

Read also: Gluc­o­Modicum: Needle-free & pain­less gluc­ose mon­it­or­ing